GTC Biotherapeutics (fka GTCB)

[n4807g]

yes and it also gives GTCB one more "interested" party. Although I am slightly disappointed that there wasn't a bigger deal in the announcement I'm more confident that GTCB has more financial backing. Now the CC is critical from the perspective of showing investors a path to sustained solvency and eventually profitability. Revenue projections on the upper limit for ATryn would help at this point. I'm also looking forward to a discussion of additional ongoing partnership discussions.

This is a good step.......I wonder if the nondisclosure is to prevent a sell-off or a run-up???? Seems insignificant to possible competitors???? Why the secrecy?????